Clinical trials: Clopidogrel, completed
Coronary Artery Disease, Diabetes Mellitus
Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study
The purpose of the SERENADE trial is to evaluate the safety and efficacy of sarpogrelate in patients with CKD or DM after DES implantation.
- Conditions
- Coronary Artery Disease, Diabetes Mellitus, Renal Insufficiency, Chronic
- Trial name
- SERENADE (NCT02294643)
- Testing
- Sarpogrelate, Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Seoul National University Bundang Hospital
Myocardial Infarction, ST Segment Elevation Myocardial Infarction (STEMI)
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
This is a prospective randomized study, which investigates the coronary microvascular function as assessed by coronary angiography after administration of ticagrelor compared with clopidogrel in patients with myocardial…
- Trial name
- MIRTOS (NCT02429271)
- Testing
- Ticagrelor, Clopidogrel, Percutaneous Coronary Intervention (PCI)
- Where
- Greece
- Volunteers
- 336 people
- Sponsor
- Hellenic Cardiovascular Research Society
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Drug Interaction
PPI and Clopidogrel Response
Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis.
- Trial name
- NCT01170533
- Testing
- omeprazole and pantoprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Florida
Myocardial Infarction
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
Percutaneous coronary intervention (PCI) with stent implantation is the preferred reperfusion strategy for treatment of acute myocardial infarction (AMI).
- Trial name
- ACCELAMI2C19 (NCT00915733)
- Testing
- cilostazol, clopidogrel (Plavix), CYP2C19
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Gyeongsang National University Hospital
Cervical Artery Dissection, Carotid Artery Dissection
To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection
This is a feasibility study to determine if a sufficient number of patients can be recruited throughout the United Kingdom and whether sufficient endpoints can be generated for a full scale therapeutic trial of anticoagulants…
- Conditions
- Cervical Artery Dissection, Carotid Artery Dissection, Vertebral Artery Dissection, Stroke
- Trial name
- CADISS (NCT00238667)
- Testing
- Antiplatelet (Aspirin, Dipyridamole, clopidogrel), Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- St George's, University of London
Atherosclerosis
TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement
Rotational atherectomy (RA) prior to angioplasty is the reference treatment for highly calcified atherosclerotic coronary lesions.
- Trial name
- TIRATROP (NCT02505399)
- Testing
- ticagrelor, clopidogrel
- Where
- 4 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Toulouse
Atrial Fibrillation, Coronary Artery Disease
Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"
The aim of this study was to assess safety of antithrombotic drug ticagrelor plus oral anticoagulation adopted in persistent or permanent AF(Atrial fibrillation) patients（CHA2DS2VASc≥2） after PCI-S with specially regard to the…
- Trial name
- NCT02206815
- Testing
- Ticagrelor+Warfarin, Clopidogrel+Aspirin+Warfarin
- Where
- 3 sites in China
- Volunteers
- 296 people
- Sponsor
- Genshan Ma
Acute Coronary Syndrome, Lipid Disorder
Polypill in Acute Coronary Syndrome
Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and healthcare costs. Effective therapies are widely available; however, adherence is low.
- Conditions
- Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
- Trial name
- POLY-ACS (NCT05514938)
- Testing
- Polypill, Usual Care (individual medications prescribed by primary cardiologist)
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Texas Southwestern Medical Center
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM (NCT00823212)
- Testing
- PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin
- Where
- 133 sites in United States, Australia and 15 more
- Volunteers
- 1,530 people
- Sponsor
- Boston Scientific Corporation
Coronary Stenoses
TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI
This study evaluates the efficacy and safety of tailored antithrombotic therapy with early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month…
- Trial name
- TAILORED-CHIP (NCT03465644)
- Testing
- Tailored antithrombotic strategy, Conventional antithrombotic strategy
- Where
- 22 sites in South Korea
- Volunteers
- 2,018 people
- Sponsor
- Duk-Woo Park, MD
Metabolism of Clopidogrel
Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug.
- Trial name
- PGXB2B (NCT01341600)
- Testing
- Clopidogrel, Omeprazole/Clopidogrel
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Acute Cardiac Syndrome, Stent Thrombosis
REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS)
The main objective of the project is to assess the long-term prognostic impact of residual platelet reactivity after optimal antiplatelet therapy in a large cohort of patients with acute coronary syndrome undergoing invasive…
- Conditions
- Acute Cardiac Syndrome, Stent Thrombosis, Platelet Function, Antiplatelet Therapy
- Trial name
- RECLOSE2-ACS (NCT01231035)
- Where
- Italy
- Volunteers
- 1,789 people
- Sponsor
- Careggi Hospital
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that…
- Conditions
- Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
- Trial name
- TRIAGE (NCT01582217)
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ischemic Stroke
Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study
The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.
- Trial name
- Bo-CRISP (NCT01843361)
- Where
- Germany
- Volunteers
- 159 people
- Sponsor
- Ruhr University of Bochum
Atherosclerotic Cardiovascular Disease
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
Clopidogrel is the most widely used P2Y12 receptor inhibitor and is the only agent of this class currently recommended in patients with stable coronary artery disease (CAD) undergoing PCI, and for the treatment of stroke or PAD.
- Trial name
- NCT03096288
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 259 people
- Sponsor
- University of Florida
Drug Drug Interaction
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects
- Trial name
- NCT05574374
- Testing
- DWP14012, DWC202202, DWC202203
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Critical Limb Ischemia
Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
Background: Up to 10% of patients with peripheral arterial disease (PAD) will develop critical limb ischemia (CLI) which is a decrease of blood flow in the arteries of the limb.
- Trial name
- RIVAL-PAD (NCT02260622)
- Testing
- rivaroxaban plus aspirin, clopidogrel plus aspirin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Coronary Artery Disease
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting.
- Trial name
- BOCLAplan (NCT01212302)
- Testing
- Optimizing ASA and clopidogrel treatment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Ruhr University of Bochum
Acute Coronary Syndrome
Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation
In view of its safety profile and the results of clinical trials, clopidogrel has become the standard treatment for patients with acute coronary syndrome (ACS) and drug eluting stent(DES) implantation.
- Trial name
- NCT00404053
- Testing
- Clopidogrel
- Sponsor
- Shenyang Northern Hospital